Brokerages Set Nkarta, Inc. (NASDAQ:NKTX) Target Price at $15.00

Shares of Nkarta, Inc. (NASDAQ:NKTX) have been given an average recommendation of “Buy” by the seven analysts that are currently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $15.00.

Several equities analysts have commented on the stock. Rodman & Renshaw began coverage on shares of Nkarta in a report on Wednesday, October 9th. They issued a “buy” rating and a $14.00 price objective on the stock. HC Wainwright lowered their price target on shares of Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, November 11th. Needham & Company LLC reduced their price objective on Nkarta from $13.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 8th. Raymond James upgraded Nkarta from an “outperform” rating to a “strong-buy” rating and set a $16.00 target price on the stock in a research note on Wednesday, August 14th. Finally, RODMAN&RENSHAW upgraded Nkarta to a “strong-buy” rating in a research note on Wednesday, October 9th.

Institutional Trading of Nkarta

Large investors have recently made changes to their positions in the company. State Board of Administration of Florida Retirement System bought a new stake in shares of Nkarta during the 1st quarter valued at approximately $147,000. Vanguard Group Inc. grew its stake in shares of Nkarta by 26.0% during the first quarter. Vanguard Group Inc. now owns 1,966,271 shares of the company’s stock worth $21,255,000 after buying an additional 405,753 shares during the last quarter. Janus Henderson Group PLC acquired a new position in shares of Nkarta during the first quarter worth $9,072,000. GAMMA Investing LLC increased its holdings in shares of Nkarta by 1,887.0% during the second quarter. GAMMA Investing LLC now owns 4,729 shares of the company’s stock worth $28,000 after buying an additional 4,491 shares in the last quarter. Finally, Simplicity Wealth LLC lifted its stake in shares of Nkarta by 136.8% in the 2nd quarter. Simplicity Wealth LLC now owns 37,486 shares of the company’s stock valued at $222,000 after acquiring an additional 21,659 shares during the last quarter. Institutional investors and hedge funds own 80.54% of the company’s stock.

Nkarta Trading Down 4.0 %

NKTX stock opened at $2.87 on Thursday. Nkarta has a 1-year low of $2.38 and a 1-year high of $16.24. The business’s 50 day simple moving average is $3.54 and its 200 day simple moving average is $5.11. The firm has a market capitalization of $202.54 million, a PE ratio of -1.53 and a beta of 0.86.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.